Article Text

Download PDFPDF
Biomarkers: to be or not to be
  1. Sule Yavuz,
  2. Lars Rönnblom
  1. Department of Medical Sciences, Rheumatology and Science for Life Laboratories, Uppsala University, Uppsala, Sweden
  1. Correspondence to Professor Sule Yavuz, Department of Medical Sciences, Rheumatology and Science for Life Laboratories, Uppsala University, Uppsala 75185, Sweden; sule.yavuz{at}medsci.uu.se

Statistics from Altmetric.com

We read with great interest the article by van den Hoogen et al 1 describing galectin-9 (Gal-9) as a novel, easy-to-measure biomarker for the interferon (IFN) signature in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). We support the views expressed by the authors that IFN signature is an important biomarker in disease activity in SLE and there is certainly a need for easier to measure biomarkers for IFN signature, but to suggest that Gal-9 could aid in clinical decision making in steering anti-IFN therapy seems premature. We know that the common …

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Contributors Both authors contributed equally to writing and editing this letter.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles